US-based, China-focused CANbridge moves into cholestatic liver disease and enzyme replacement therapy via two deals. Plus deals involving LegoChem, TransThera, Morepen, Daiichi Sankyo, Geneseeq, Innocare, Biosplice, Sirnaomics and Walvax.

In this week's podcast version of Five Must-Know Things, hear about possible new life for Tecfidera, activist investors and GSK, a new mRNA vaccine in Europe, diversity in clinical trials, and a look at last year’s drug launches.

Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.

In this week's podcast version of Five Must-Know Things, hear about adenovirus vaccines and blood clots, Lilly’s new moves in genetic diseases, the efficacy debate over Chinese COVID-19 vaccines, putting a price tag on innovation, and Sanofi’s bullishness on IL-2.

French giant makes its biggest single investment to date in Asia as it prepares to build up regional vaccine production capacity, in part to help prepare for future pandemics. 

In this week's podcast version of Five Must-Know Things, hear about whether safety concerns may affect JAK inhibitors, Takeda’s strategic R&D plans, Cigna’s psoriasis insurance program, Phase III readouts to look for, and an overview of the global pharma R&D pipeline.